Reference Interval: 27 - 94 ug/L ( M and F)
New method Cisbio CgA from 12/5/2014.
Note: Correlation with the previous Dako CgA method. Cisbio CgA results are higher and quite different from the Dako method - no conversion factor.
Peter MacCallum Cancer Centre(VCCC)- BIochemistry laboratory 85595406
Interpretation:
Serum Chromogranin A (CgA) is the most established neuroendocrine neoplasm (NEN) marker for diagnosis in high risk populations, monitoring progression or treatment response. Test performance is better with advanced than localised disease, higher disease burden and with tumours of gastroenteropancreatic origin.
Non-NEN causes of CgA elevation include: renal failure, atrophic gastritis, liver impairment, cardiac failure, inflammatory bowel disease, PPI or histamine type-2 receptor antagonist therapy, and other non-neuroendocrine tumours.
Correlation with disease progression may be lost during treatment with somatostatin analogues as these significantly reduce CgA synthesis and release from tumour cells but may not indicate a reduction in tumour mass.
For patients being monitored, serial CgA should be measured using the same assay.
References:
1. COSA consensus guidelines for the diagnosis and management of neuroendocrine neoplasms (2022)
2. Up-to-Date. Accessed 15/03/2024
|